文献速递泌尿生殖MR

特征指数(S-index)作为扩散MRI生物标志物在提升临床显著前列腺癌诊断及减少不必要活检中的潜力

Potential of the signature index (S-index), a diffusion MRI Biomarker, to enhance diagnosis of clinically significant prostate cancer and decrease the rate of unnecessary biopsies.
PubMed 文献 · Eur J Radiol · 2026-03-14

回顾性研究纳入180例患者264个靶病灶(95个癌灶),行MRI-US融合引导前列腺活检,计算非高斯扩散标志物S-index与sADC并与PI-RADS比较。外周带S-index与sADC对临床显著癌(ISUP≥2)的AUC约0.90–0.92,高于PI-RADS的0.70;移行带各标志物AUC约0.82。外周带PI-RADS>3病灶中sADC减少22.4%、S-index减少21%的不必要活检。

要点

  • 外周带临床显著前列腺癌(ISUP≥2)的S-index与sADC的AUC约0.90–0.92,高于PI-RADS的0.70。
  • 外周带PI-RADS>3病灶中,sADC减少22.4%、S-index减少21%的不必要活检。
  • 移行带各标志物诊断性能相似(AUC约0.82),S-index第85百分位减少9.5%不必要活检。

核心结论

  • S-index及其他扩散MRI生物标志物对临床显著前列腺癌分类表现出较强性能,可能成为提升MRI临床价值、改善前列腺癌管理的重要一步。

研究设计与样本

  • 回顾性研究,纳入180例患者共264个靶病灶(其中95个为癌灶),均行MRI-US融合引导前列腺活检;采用多参数MRI包括三个b值(0、200、1500 s/mm²)的扩散加权成像计算sADC与S-index;以ROC分析评估诊断性能并与PI-RADS比较。

诊断标准与关键数值

  • 临床显著癌定义为ISUP≥2;外周带临床显著癌S-index全局值103.0±30.2、第85百分位139.4±31.6,移行带分别为106.6±32.3、142.2±33.9,均显著高于其他病灶及正常组织(外周带45.7±27.9、71.1±38.1;移行带67.6±25.4、93.0±30.5,p<0.001);外周带S-index全局值、第85百分位及sADC的AUC分别为0.92(0.87–0.95)、0.90(0.86–0.94)、0.92(0.87–0.95),PI-RADS单独AUC为0.70(0.59–0.70);移行带各标志物AUC约0.82。

临床应用与阅片要点

  • 在外周带,S-index与sADC可辅助PI-RADS>3病灶的分类,sADC减少22.4%、S-index减少21%的不必要活检;移行带S-index第85百分位减少9.5%不必要活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the potential of the signature index (S-index) and the shifted apparent diffusion coefficient (sADC), both markers of non-Gaussian diffusion, for the diagnosis of prostate cancer.

METHODS: This retrospective study included 180 patients with 264 target lesions (95 cancerous) who underwent MRI-US fusion-guided prostate biopsy. Multiparametric MRI, including diffusion-weighted imaging with three b values (0, 200, and 1500 s/mm2), was performed to calculate sADC and the S-index. The diagnostic performances of these biomarkers were assessed using ROC analyses and compared with PI-RADS.

RESULTS: The global S-index and its 85th percentile values for clinically significant cancers (ISUP ≥ 2) in both the peripheral zone (PZ: 103.0 ± 30.2 and 139.4 ± 31.6) and the transition zone (TZ: 106.6 ± 32.3 and 142.2 ± 33.9) were significantly higher (p < 0.001) than those for all other lesions and normal tissue (PZ: 45.7 ± 27.9 and 71.1 ± 38.1; TZ: 67.6 ± 25.4 and 93.0 ± 30.5). In the PZ, the S-index (global and 85th percentile) and sADC showed higher diagnostic performance for classifying clinically significant cancers (AUC = 0.92 [0.87-0.95], 0.90 [0.86-0.94], and 0.92 [0.87-0.95], respectively) compared with PI-RADS alone (AUC = 0.70 [0.59-0.70]), whereas performance in the TZ was similar across markers (AUC ∼ 0.82). The reduction in unnecessary biopsies for PI-RADS > 3 lesions in the PZ was 22.4% with sADC and 21% with the S-index. In the TZ, the highest reduction rate was achieved with the S-index 85th percentile (9.5%).

CONCLUSION: The S-index and other diffusion MRI biomarkers demonstrate strong performance for the classification of clinically significant prostate cancer and may represent an important step toward enhancing the clinical value of MRI for improving prostate cancer management.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wibulpolprasert P, Bihan DL, Leelarujijaroen P, et al. Potential of the signature index (S-index), a diffusion MRI Biomarker, to enhance diagnosis of clinically significant prostate cancer and decrease the rate of unnecessary biopsies. Eur J Radiol. 2026. PMID: 41875674. doi:10.1016/j.ejrad.2026.112788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。